Amanpreet Kaur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4420337/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell, 2020, 77, 633-644.e5.	4.5	45
2	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clinical Cancer Research, 2020, 26, 5709-5719.	3.2	17
3	Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discovery, 2019, 9, 82-95.	7.7	100
4	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discovery, 2019, 9, 64-81.	7.7	260
5	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	3.2	253
6	Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clinical Cancer Research, 2017, 23, 3181-3190.	3.2	30
7	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Research, 2017, 77, 5873-5885.	0.4	26
8	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 2016, 532, 250-254.	13.7	290
9	In the Wnt-er of life: Wnt signalling in melanoma and ageing. British Journal of Cancer, 2016, 115, 1273-1279.	2.9	54
10	<scp>W</scp> nt5 <scp>A</scp> promotes an adaptive, senescentâ€like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 184-195.	1.5	77
11	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discovery, 2013, 3, 1378-1393.	7.7	197